Asenapine — Membership Pricing

Other medications in Mental Health

• Atomoxetine
• Brexanolone
• Brexpiprazole
• Bupropion
• Buspirone
• Cariprazine
• Chlordiazepoxide
• Chlorpromazine

About Asenapine

Asenapine is an important medication often prescribed for managing conditions like schizophrenia and bipolar I disorder. Understanding your treatment, including how it works and its cost, is key. At TheDrugClub, we're dedicated to helping our members navigate prescription expenses, offering potential savings on medications like asenapine to make managing your health more affordable.

What is Asenapine and What Does It Treat?

Asenapine is an atypical antipsychotic medication primarily used to treat adults with schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. It is also approved for adolescents with bipolar I disorder. By helping to regulate brain chemistry, asenapine can reduce symptoms such as hallucinations, delusions, disorganized thinking, and severe mood swings, allowing individuals to experience greater stability and improved daily functioning.

How Does Asenapine Work?

Asenapine works by influencing the activity of several neurotransmitters in the brain, particularly dopamine and serotonin. These chemical messengers play crucial roles in mood, perception, and behavior. By blocking specific receptors for dopamine and serotonin, asenapine helps to rebalance these brain chemicals. This action contributes to its

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Asenapine is approved for (FDA label)

Asenapine sublingual tablet(s) is indicated for: Bipolar I disorder [see Clinical Studies ( 14.2 )] Adjunctive treatment to lithium or valproate in adults Asenapine is an atypical antipsychotic indicated for ( 1 ): Bipolar I disorder Adjunctive treatment to lithium or valproate in adults

Source: Read the full FDA label on DailyMed. Label effective date: November 25, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Asenapine (FDA label)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Asenapine is not approved for the treatment of patients with dementia –related psychosis. [see Warnings and Precautions ( 5.1 , 5.2 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Asenapine is not approved for the treatment of patients with dementia –related psychosis. ( 5.1 , 5.2 )

Source: FDA prescribing information (DailyMed). Set ID: 3512687b-d1c7-45c4-8822-3a2ad53575a5. SPL document ID: 446e6925-ccb1-e388-e063-6294a90aa5de. Label effective date: November 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Asenapine (FDA label)

Asenapine sublingual tablets, 5 mg, black cherry flavor, are White, Round, FFBE Tablets, debossed “Σ” on one side and “16” on the other side. Asenapine sublingual tablets, 10 mg, black cherry flavor, are White, Round, FFBE Tablets, debossed “Σ” on one side and “17” on the other side. Sublingual tablets, black cherry flavor: 5 mg and 10 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3512687b-d1c7-45c4-8822-3a2ad53575a5. SPL document ID: 446e6925-ccb1-e388-e063-6294a90aa5de. Label effective date: November 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Asenapine (FDA label)

The following adverse reactions are discussed in more detail in other sections of the labeling: Use in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions ( 5.1 and 5.2 )] Neuroleptic Malignant Syndrome [see Warnings and Precautions ( 5.3 )] Tardive Dyskinesia [see Warnings and Precautions ( 5.4 )] Metabolic Changes [see Warnings and Precautions ( 5.5 )] Hypersensitivity Reactions [see Contraindications, Warnings and Precautions ( 5.6 )] Orthostatic Hypotension, Syncope, and other Hemodynamic Effects [see Warnings and Precautions ( 5.7 )] Falls [see Warnings and Precautions ( 5.8 )] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions ( 5.9 )] QT Interval Prolongation [see Warnings and Precautions ( 5.10 )] Hyperprolactinemia [see Warnings and Precautions ( 5.11 )] Seizures [see Warnings and Precautions ( 5.12 )] Potential for Cognitive and Motor Impairment [see Warnings and Precautions ( 5.13 )] Body Temperature Regulation [see Warnings and Precautions ( 5.14 )] Dysphagia [see Warnings and Precautions ( 5.15 )] The most common adverse reactions (≥5% and at least twice the rate of placebo) reported during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.

Source: FDA prescribing information (DailyMed). Set ID: 3512687b-d1c7-45c4-8822-3a2ad53575a5. SPL document ID: 446e6925-ccb1-e388-e063-6294a90aa5de. Label effective date: November 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Asenapine (FDA label)

Asenapine is contraindicated in patients with: Severe hepatic impairment (Child-Pugh C) [see Specific Populations ( 8.7 ), Clinical Pharmacology ( 12.3 )]. A history of hypersensitivity reactions to asenapine. Reactions have included anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6 )]. Severe hepatic impairment (Child-Pugh C). ( 8.7 , 12.3 ) Known hypersensitivity to asenapine, or to any components in the formulation. ( 4 , 5.6 , 17 )

Source: FDA prescribing information (DailyMed). Set ID: 3512687b-d1c7-45c4-8822-3a2ad53575a5. SPL document ID: 446e6925-ccb1-e388-e063-6294a90aa5de. Label effective date: November 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Asenapine (FDA label)

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack). ( 5.2 ) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring. ( 5.3 ) Tardive Dyskinesia: Discontinue if clinically appropriate. ( 5.4 ) Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain. ( 5.5 ) Orthostatic Hypotension: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope. ( 5.7 ) Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia.

Source: FDA prescribing information (DailyMed). Set ID: 3512687b-d1c7-45c4-8822-3a2ad53575a5. SPL document ID: 446e6925-ccb1-e388-e063-6294a90aa5de. Label effective date: November 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Asenapine (FDA label)

Antihypertensive Drugs: Asenapine may cause hypotension. ( 5.7 , 7.1 , 12.3 ) Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with asenapine. ( 7.1 , 12.3 ) 7.1 Drugs Having Clinically Important Drug Interactions with Asenapine Table 12: Clinically Important Drug Interactions with Asenapine Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Antihypertensive Drugs Because of its α 1 -adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents [see Warnings and Precautions ( 5.7 )] . Monitor blood pressure and adjust dosage of antihypertensive drug accordingly. Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) Asenapine is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when asenapine is used with fluvoxamine at 25 mg administered twice daily [see Clinical Pharmacology ( 12.3 )]. However, the tested fluvoxamine dose was suboptimal.

Source: FDA prescribing information (DailyMed). Set ID: 3512687b-d1c7-45c4-8822-3a2ad53575a5. SPL document ID: 446e6925-ccb1-e388-e063-6294a90aa5de. Label effective date: November 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.